Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology. Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system. Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities. Get the full story […]
